Almstead Neil Gregory, an insider at PTC Therapeutics Inc (PTCT), purchased 109,035 shares at a price of $18.01 each on November 24, 2025, amounting to a total transaction value of $1.96 million. Following this acquisition, Gregory holds a total of 109,035 shares in the company.
PTC Therapeutics, headquartered in Warren, New Jersey, is a biopharmaceutical firm focused on developing clinically differentiated medicines for rare disorders. The company has a market capitalization of $6.9 billion and reported a price-to-earnings ratio of 9.21, with earnings per share at 8.53. Its portfolio includes products like Translarna and Emflaza for Duchenne muscular dystrophy, and Upstaza, a gene therapy for AADC deficiency.
Insider buying can often signal confidence in a company's future. However, investors are advised to consider such transactions as one of many data points, rather than the sole basis for investment decisions. Patterns of activity among multiple insiders over time can provide a more comprehensive view of sentiment within the company.
PTC Therapeutics is set to announce its upcoming earnings on May 4, 2026, with an estimated EPS of $-0.64 and revenue of $204.8 million, followed by another report on August 5, 2026, estimating an EPS of $-0.54 and revenue of $222.6 million.